Affiliations: [a]
Department of Pharmacology, Basic College of Medicine, Jilin University, Changchun, People’s Republic of China | [b] Cadre’s Ward, The First Hospital of Jilin University, Changchun, People’s Republic of China
Correspondence:
[*]
Correspondence to: Prof. Chunyan Wang, Cadre’s Ward, The First Hospital of Jilin University, Changchun 130021, People’s Republic of China. Tel.: +86 13756661655; E-mail: wang_chuny@jlu.edu.cn and Prof. Li Chen, Department of Pharmacology, Basic College of Medicine, Jilin University, 126 Xinmin Street, Changchun 130021, People’s Republic of China. Tel.: +86 0431 85619799; E-mail: chenl@jlu.edu.cn.
Abstract: Glutamate is the main excitatory neurotransmitter in the brain, and its excitatory neurotoxicity is closely related to the occurrence and development of Alzheimer’s disease. However, increasing evidence shows that in the process of Alzheimer’s disease, glutamate is not only limited to its excitotoxicity as a neurotransmitter but also related to the disorder of its metabolic balance. The balance of glutamate metabolism in the brain is an important determinant of central nervous system health, and the maintenance of this balance is closely related to glutamate uptake, glutamate circulation, intracellular mitochondrial transport, and mitochondrial metabolism. In this paper, we intend to elaborate the key role of mitochondrial glutamate metabolism in the pathogenesis of Alzheimer’s disease and review glutamate metabolism in mitochondria as a potential target in the treatment of Alzheimer’s disease.
